OmicsBank Raises $2.25 Million in Seed Funding
OmicsBank, a company specializing in AI-ready clinical data infrastructure, has announced the completion of a $2.25 million seed funding round. The funding was led by Redesign Health, a global venture capital and technology firm. OmicsBank, based in San Francisco, California, aims to provide a comprehensive platform for pharmaceutical companies, biotech firms, and AI labs, facilitating drug development and healthcare advancements.
Company Overview
OmicsBank offers a clinical data infrastructure platform that connects fragmented hospital data to aid drug development and healthcare AI initiatives. The company's system is already in use across South Asia, Southeast Asia, and the Middle East, where it standardizes and de-identifies patient-level datasets, making them directly accessible for research and AI applications. These datasets include various structured data types such as electronic health records (EHR), imaging, and multi-omics data, all managed under strict data privacy regulations.
Founders and Leadership
OmicsBank was co-founded by Sumit Sinha and Vijay Goel. The leadership team has been instrumental in driving the company's vision of transforming clinical data into actionable insights for the healthcare industry.
Use of Funds
The newly acquired funds will be utilized to expand OmicsBank's operations across the United States and further develop its clinical data network in Asia and the Middle East. The company plans to strengthen its collaborations with health systems, pharmaceutical and biotechnology companies, contract research organizations (CROs), and AI developers.
Lead Investor
Redesign Health, known for its investments in health tech and innovation, led this funding round. The investment underscores the potential of OmicsBank's platform to revolutionize how clinical data is used in drug development and AI-driven healthcare solutions.
For more information, visit OmicsBank's website.